anlotinib + carelizumab + oxitinib

This drug refers to a combination therapy consisting of three agents: anlotinib, carelizumab, and oxitinib. Anlotinib is a novel oral small molecule tyrosine kinase inhibitor targeting multiple receptor tyrosine kinases involved in tumor angiogenesis and growth, including VEGFR, FGFR, PDGFR, and c-Kit. Carelizumab (also known as camrelizumab) is a humanized monoclonal antibody that targets programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Oxitinib is described in the literature as a new EGFR tyrosine kinase inhibitor; however, it may refer to axitinib—a VEGFR TKI—though it was specifically named “oxitinib” in published reports[1][2]. This triple regimen has been used experimentally alongside radiotherapy for glioblastoma patients intolerant to temozolomide and has shown promising results with improved progression-free survival and overall survival compared to historical controls[1][2].

Brand names

Catequentinib

Other names

anlotinib + camrelizumab + oxitinib